NewslettersSep 04, 2025
Porton Newsletter - August 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Sep 01, 2025
Porton to Showcase Integrated CDMO Expertise at BIOSPAIN 2025
Porton to Showcase Integrated CDMO Expertise at BIOSPAIN 2025
News Aug 29, 2025
Porton's End-to-End CMC Development Accelerates Market Approval for Innovative ALK Inhibitor Dirozalkib (Xuanfeining) Tablets
As the sole CDMO service provider for the active pharmaceutical ingredient (API) of Dirozalkib
News Aug 29, 2025
Porton Supports BioNova's BN104 Program in Achieving Milestone Entry into Overseas Markets
BioNova & Porton Annual Collaboration Review and Award Ceremony
News Aug 22, 2025
PORTON 2025 H1 PERFORMANCE HIGHLIGHTS
PORTON 2025 H1 PERFORMANCE HIGHLIGHTS
News Aug 20, 2025
Porton Nominated for the 2025 Sedex Supply Chain Award
Porton Pharma Solutions Ltd. (“Porton”) was honored with a nomination for the Positive Endeavors Award at the 2025 Sedex Supply Chain Award Ceremony. The recognition highlights Porton’s unwavering commitment to sustainability and responsible business practices.
News Aug 19, 2025
Porton to Showcase Integrated CDMO Expertise at CPHI Frankfurt 2025
The 2025 CPhI Frankfurt event will take place from October 28–30 at Messe Frankfurt, Germany, gathering over 62,000 attendees and 2,400 exhibitors from more than 166 countries.
NewslettersAug 04, 2025
Porton Newsletter - July 2025 Recap
Technical Enabling Services & Solutions Company Events Marketing Activities
News Jul 31, 2025
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
